| XLS |
|
|
|
|
|
||
€ million |
Q2 – 2014 |
Q2 – 2013 |
Jan.–June 2014 |
Jan.–June 2013 |
||
|
||||||
Sales |
2,795.5 |
2,743.9 |
5,409.4 |
5,404.3 |
||
Royalty, license and commission income |
67.6 |
97.2 |
118.5 |
197.3 |
||
Total revenues |
2,863.1 |
2,841.1 |
5,527.9 |
5,601.6 |
||
|
|
|
|
|
||
Cost of sales |
–828.6 |
–768.0 |
–1,565.1 |
–1,492.0 |
||
Gross profit |
2,034.5 |
2,073.1 |
3,962.8 |
4,109.6 |
||
|
|
|
|
|
||
Marketing and selling expenses |
–601.5 |
–616.3 |
–1,151.0 |
–1,184.6 |
||
Royalty, license and commission expenses |
–139.1 |
–156.5 |
–275.4 |
–292.8 |
||
Administration expenses |
–151.0 |
–137.5 |
–283.3 |
–270.2 |
||
Other operating expenses and income |
–110.4 |
–114.5 |
–177.2 |
–298.5 |
||
Research and development costs |
–394.1 |
–373.5 |
–773.0 |
–779.7 |
||
Amortization of intangible assets |
–197.4 |
–209.4 |
–393.6 |
–419.0 |
||
Operating result (EBIT) |
441.0 |
465.4 |
909.3 |
864.8 |
||
|
|
|
|
|
||
Financial result |
–50.2 |
–48.5 |
–84.9 |
–107.2 |
||
Profit before income tax |
390.8 |
416.9 |
824.4 |
757.6 |
||
|
|
|
|
|
||
Income tax |
–84.8 |
–100.8 |
–191.0 |
–172.5 |
||
Profit after tax |
306.0 |
316.1 |
633.4 |
585.1 |
||
|
|
|
|
|
||
of which attributable to Merck KGaA shareholders (net income) |
303.3 |
316.0 |
628.5 |
582.0 |
||
of which attributable to non-controlling interests |
2.7 |
0.1 |
4.9 |
3.1 |
||
|
|
|
|
|
||
Earnings per share (in €) |
|
|
|
|
||
basic1 |
0.70 |
0.73 |
1.45 |
1.34 |
||
diluted1 |
0.70 |
0.73 |
1.45 |
1.34 |
||